NCT02546102: An ongoing trial by Precision Life Sciences Group
This trial is ongoing. It must report results 7 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT02546102 |
|---|---|
| Title | A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 31, 2024 |
| Completion date | Dec. 31, 2025 |
| Required reporting date | Dec. 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 15, 2026 |
| Days late | None |